Corton Capital’s Filana Therapeutics FLNA Stock Holding History

Corton Capital’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5,516	Closed	-$231K	–	364
2022 Q3	$231K	Buy	+5,516	New	+$149K	0.28%	161

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCM

Gallacher Capital Management Lone Tree, Colorado $178M AUM 29.29% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Corton Capital's FLNA Position: Q4 2022 in Review

Corton Capital sold out of Filana Therapeutics (FLNA) in Q4 2022, closing a stake of 5,516 shares — an estimated $231K sold.

Corton Capital first reported a position in FLNA in Q3 2022 and held it in 1 quarter. The position peaked at $231K in Q3 2022. 153 funds tracked by Wall St. Rank hold FLNA as of Q4 2022.

Corton Capital reported no remaining Filana Therapeutics position as of Q4 2022 after selling out during the quarter.
Corton Capital sold 5,516 Filana Therapeutics shares in Q4 2022, an estimated $231K.
Corton Capital first reported a position in Filana Therapeutics in Q3 2022 and held it in 1 quarter.
Corton Capital's Filana Therapeutics position peaked at $231K in Q3 2022.
153 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2022.

Based on Corton Capital's 13F filing for Q4 2022, filed 14 Feb 2023.